Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: A 16-week randomized, double-blind, placebo-controlled study

Diabetes

Volumn 54, Issue 9, 2005, Pages 2787-2794

  Lautamäki, Riikka ^a,d   Airaksinen, K E Juhani ^a   Seppänen, Marko ^a   Toikka, Jyri ^a   Luotolahti, Matti ^a   Ball, Elizabeth ^b   Borra, Ronald ^a   Härkönen, Risto ^a   Iozzo, Patricia ^a,c   Stewart, Murray ^b   Knuuti, Juhani ^a   Nuutila, Pirjo ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b GLAXOSMITHKLINE   (United Kingdom)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEMOGLOBIN A1C; NITRIC ACID DERIVATIVE; PLACEBO; ROSIGLITAZONE; STATINE DERIVATIVE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EUGLYCEMIC HYPERINSULINEMIC CLAMP TEST; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEART MUSCLE; HUMAN; HYPERINSULINEMIA; IMAGE ANALYSIS; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIUM; THIAZOLIDINEDIONES;

EID: 24144496019     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.9.2787     Document Type: Article

References (47)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
2. Aronson D, Rayfield EJ, Chesebro JH: Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 126:296-306, 1997
3. Camici P, Ferrannini E, Opie LH: Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 32:217-238, 1989
4. Maki M, Luotolahti M, Nuutila P, Iida H, Voipio-Pulkki LM, Ruotsalainen U, Haaparanta M, Solin O, Hartiala J, Harkonen R, Knuuti J: Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation 93:1658-1666, 1996
5. Maki M, Nuutila P, Laine H, Voipio-Pulkki LM, Haaparanta M, Solin O, Knuuti JM: Myocardial glucose uptake in patients with NIDDM and stable coronary artery disease. Diabetes 46:1491-1496, 1997
6. Utriainen T, Takala T, Luotolahti M, Ronnemaa T, Laine H, Ruotsalainen U, Haaparanta M, Nuutila P, Yki-Jarvinen H: Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 41:555-559, 1998
7. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG: Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 51:3020-3024, 2002
8. Jagasia D, Whiting JM, Concato J, Pfau S, McNulty PH: Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 103:1734-1739, 2001
9. Yokoyama I, Yonekura K, Ohtake T, Kawamura H, Matsumoto A, Inoue Y, Aoyagi T, Sugiura S, Omata M, Ohtomo K, Nagai R: Role of insulin resistance in heart and skeletal muscle F-18 fluorodeoxyglucose uptake in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 7:242-248, 2000
10. Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS, Radda GK, Ferrannini E: Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease: a study with positron emission tomography. J Clin Invest 98:2094-2099, 1996
11. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688, 1999
12. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82, 1998
13. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, Masuda Y: Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 87:596-602, 2000
14. Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104:2588-2594, 2001
15. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K: Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 51:1110-1117, 2002
16. Virtanen KA, Hallsten K, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, Ronnemaa T, Knuuti J, Huupponen R, Lonnroth P, Nuutila P: Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52:283-290, 2003
17. Hallsten K, Virtanen KA, Lonnqvist F, Sipila H, Oksanen A, Viljanen T, Ronnemaa T, Viikari J, Knuuti J, Nuutila P: Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479-3485, 2002
18. Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P: Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care 26:2069-2074, 2003
19. Hallsten K, Virtanen KA, Lonnqvist F, Janatuinen T, Turiceanu M, Ronnemaa T, Viikari J, Lehtimaki T, Knuuti J, Nuutila P: Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med 21:1280-1287, 2004
20. Imaging guidelines for nuclear cardiology procedures, part 2. American Society of Nuclear Cardiology. J Nucl Cardiol 6:G47-G84, 1999
21. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 55:613-618, 1977
22. Grossman W, Jones D, McLaurin LP: Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56:56-64, 1975
23. Hamacher K, Coenen HH, Stocklin G: Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238, 1986
24. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M: The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916, 1977
25. Stolen KQ, Kemppainen J, Kalliokoski KK, Luotolahti M, Viljanen T, Nuutila P, Knuuti J: Exercise training improves insulin-stimulated myocardial glucose uptake in patients with dilated cardiomyopathy. J Nucl Cardiol 10:447-455, 2003
26. Ng CK, Soufer R, McNulty PH: Effect of hyperinsulinemia on myocardial fluorine-18-FDG uptake. J Nucl Med 39:379-383, 1998
27. Marinho NV, Keogh BE, Costa DC, Lammerstma AA, Ell PJ, Camici PG: Pathophysiology of chronic left ventricular dysfunction: new insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation 93:737-744, 1996
28. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 351:1106-1118, 2004
29. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176, 2004
30. Bell DS: Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol 93:49B-52B, 2004
31. Cave AC, Ingwall JS, Friedrich J, Liao R, Saupe KW, Apstein CS, Eberli FR: ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation 101:2090-2096, 2000
32. Sun D, Nguyen N, DeGrado TR, Schwaiger M, Brosius FC III: Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes. Circulation 89:793-798, 1994
33. Zaninetti D, Greco-Perotto R, Jeanrenaud B: Heart glucose transport and transporters in rat heart: regulation by insulin, workload and glucose. Diabetologia 31:108-113, 1988
34. Randle PJ, Newsholme EA, Garland PB: Regulation of glucose uptake by muscle. 8: effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 93:652-665, 1964
35. Fang ZY, Prins JB, Marwick TH: Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25:543-567, 2004
36. McNulty PH: Comparison of local and systemic effects of insulin on myocardial glucose extraction in ischemic heart disease. Am J Physiol Heart Circ Physiol 278:H741-H747, 2000
37. Rodrigues B, Cam MC, McNeill JH: Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27:169-179, 1995
38. Yakubu-Madus FE, Stephens TW, Johnson WT: Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. Diabetes Obes Metab 2:155-163, 2000
39. Racette SB, Davis AO, McGill JB, Klein S: Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism 51:169-174, 2002
40. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK: Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 95:7614-7619, 1998
41. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210, 1994
42. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL: Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135-144, 2004
43. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, Patel J, Freed M: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25:2058-2064, 2002
44. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1:165-172, 1999
45. Hollenberg NK: Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115 (Suppl. 8A):111S-115S, 2003
46. Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Laragione T, Salio M, Savino C, Melucci S, Santangelo F, Scanziani E, Masson S, Ghezzi P, Latini R: Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 37:959-968, 2004
47. Bagi Z, Koller A, Kaley G: PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 286:H742-H748, 2004